Biogen Completes $5.3 Billion Acquisition of Apellis Pharmaceuticals, Secures $2 Billion Term Loan

summarizeSummary

Biogen has completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding key commercial products and securing a $2 billion term loan to help finance the deal.

check_boxKey Events

• Acquisition of Apellis Pharmaceuticals Completed

  Biogen finalized the acquisition of Apellis Pharmaceuticals for approximately $5.3 billion in cash, plus contingent value rights (CVRs) for up to $582 million based on SYFOVRE® net sales.

• $2 Billion Term Loan Secured

  Biogen entered into a $2 billion unsecured term loan facility (split into a 364-day and a two-year tranche) to fund a portion of the acquisition consideration.

• Strategic Portfolio Expansion

  The acquisition adds commercialized products EMPAVELI® and SYFOVRE®, expected to bolster near-term growth and be accretive to non-GAAP diluted EPS by 2027.

• Contingent Value Rights (CVRs) Issued

  Former Apellis shareholders received non-transferable CVRs, entitling them to potential cash payments of up to $4.00 per CVR upon achievement of specific annual net sales milestones for SYFOVRE® by 2031.

auto_awesomeAnalysis

Biogen has finalized its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion in cash, plus contingent value rights (CVRs) worth up to an additional $582 million based on future SYFOVRE® sales. This major transaction, previously announced, significantly expands Biogen's portfolio with two commercialized products, EMPAVELI® and SYFOVRE®, and is expected to be accretive to non-GAAP diluted EPS by 2027. To fund a portion of the acquisition, Biogen secured a $2 billion unsecured term loan. The completion of this acquisition marks a significant strategic move for Biogen, aiming to bolster its near-term growth and expand into nephrology.